Downloaded from https://journals.lww.com/nuclearmed by IJFFeEaHn1cfHPNrSC3daWj6PKnKQFhW+EMTsaf/WKf0u7T8lHlKpTwHXzgWSaBAry8173SbICnQ9fMrliMqOSPTWOGqctLQ51ihHKNTgwKOMLCGlmWHvq9W+z1ct4B9 on 04/17/2020 18 F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence Fahad Marafi, MD, KBNM,* Arun Sasikumar, MD,† Wael Fathallah, FRCR,‡ and Abdulredh Esmail, MD, KBNM* Abstract: A 64-year-old man with a known case of right parietal lobe glio- blastoma multiforme operated on in August 2018 was referred for 18 F-FDG PET/CTwith a clinical suspicion of recurrence. He underwent 18 F-FDG and 18 F-PSMA 1007 scans. Both the scans showed intense tracer uptake in right parietal lobe lesion, which concurred with MRI findings of recurrent disease and was later proven on histopathologic examination as recurrence. Our case highlights the feasibility of 18 F-PSMA 1007 PET/CT imaging of suspected glioblastoma recurrence. Considering its similarity to PSMA-617, it may be used as a surrogate imaging tracer for potential theranostic application using alpha or beta emitters. Key Words: 18 F-PSMA 1007, glioblastoma multiforme, PET/CT (Clin Nucl Med 2020;45: e61–e62) REFERENCES 1. Sasikumar A, Joy A, Pillai MR, et al. Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors—preliminary analysis. Clin Nucl Med. 2017;42:e41–e48. 2. Sasikumar A, Kashyap R, Joy A, et al. Utility of 68Ga-PSMA-11 PET/CT in imaging of glioma—a pilot study. Clin Nucl Med. 2018;43:e304–e309. 3. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–495. 4. Freitag MT, Kesch C, Cardinale J, et al. Simultaneous whole-body (18) F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of pa- tients with prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2018; 45:340–347. 5. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–688. 6. Giesel FL, Will L, Kesch C, et al. Biochemical recurrence of prostate cancer: initial results with [ 18 F]PSMA-1007 PET/CT. J Nucl Med. 2018;59:632–635. 7. Kesch C, Vinsensia M, Radtke JP, et al. Intraindividual comparison of 18 F-PSMA-1007 PET/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, proof- of-concept study. J Nucl Med. 2017;58:1805–1810. 8. Seifert R, Schafigh D, Bögemann M, et al. Detection of local relapse of pros- tate cancer with 18F-PSMA-1007. Clin Nucl Med. 2019;44:e394–e395. 9. Pianou NK, Stavrou PZ, Vlontzou E, et al. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18 F-PSMA PET/CT. Hell J Nucl Med. 2019;22:6–9. 10. Giesel FL, Cardinale J, Schafer M, et al. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43:1929–1930. Received for publication May 1, 2019; revision accepted May 2, 2019. From the *Jaber Alahmad Centre for Molecular Imaging, Shuwaikh, Kuwait; †St Gregorios International Cancer Care Centre, Parumala, Kerala, India; and ‡Kuwait Cancer Control Centre, Shuwaikh, Kuwait. Conflicts of interest and sources of funding: none declared. Correspondence to: Arun Sasikumar, MD, Department of Nuclear Medicine, St Gregorios International Cancer Care Centre, Parumala, Pathanmthitta, Kerala, India. E-mail: sasikumararun@gmail.com. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0363-9762/20/4501–0e61 DOI: 10.1097/RLU.0000000000002668 INTERESTING IMAGE Clinical Nuclear Medicine • Volume 45, Number 1, January 2020 www.nuclearmed.com e61 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.